Moreover, expression changes in CD105, TGFβ1, VEGF, HIF-1a and tumor vasculature in the presence of low and high doses of bevacizumab in nude mouse models and clinical specimens require further elucidation. The gene discussed is TGFB1; the disease is neoplasm.